Global healthcare company Viatris Inc (Nasdaq:VTRS) announced on Tuesday the appointment of Matthew J Maletta as chief legal officer (CLO), effective 9 February 2026.
This follows the transition of the company's current CLO, Brian Roman, after more than 20 years with Viatris and its predecessor company, Mylan. Roman will stay on through 1 April 2026, to ensure a smooth transition.
Maletta has nearly 30 years of legal experience and expertise in leading legal teams for both generic and branded pharmaceutical companies. From 2015 to 2025, he served as executive vice president, chief legal officer and corporate secretary at Endo, where he oversaw Endo's merger with Mallinckrodt and the subsequent spin-off of Par Health.
Earlier, Maletta spent over a decade in the legal department at Allergan, rising to vice president, associate general counsel and corporate secretary.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream